Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B

BACKGROUND: Immunotherapeutic approaches designed to augment T and B cell mediated killing of tumor cells has met with clinical success in recent years suggesting tremendous potential for treatment in a broad spectrum of tumor types. After complex recognition of target cells by T and B cells, delive...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheung, Lawrence H., Zhao, Yunli, Alvarez-Cienfuegos, Ana, Mohamedali, Khalid A., Cao, Yu J., Hittelman, Walter N., Rosenblum, Michael G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668111/
https://www.ncbi.nlm.nih.gov/pubmed/31362764
http://dx.doi.org/10.1186/s13046-019-1333-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668111/
https://www.ncbi.nlm.nih.gov/pubmed/31362764
http://dx.doi.org/10.1186/s13046-019-1333-6

Ejemplares similares